Session: 723. Allogeneic Transplantation: Long-term Follow-up, Complications, and Disease Recurrence: Poster III
Hematology Disease Topics & Pathways:
Research, Clinical Research, Health outcomes research, Real-world evidence, Survivorship
Methods: we evaluated 3477 consecutive allo-HCT recipients at our center between 2008 to 2022. We calculated HCT-CI, aHCT-CI, oHCT-CI, and SCI scores, and compared the distribution of these four scoring systems in this population. Cumulative incidence curves of NRM and Kaplan-Meier curves of OS were computed for each of the collapsed risk groups: 0, 1 to 2, 3 or more. Cause-specific Cox regression and Cox regression were used to evaluate the association of each of the scores with NRM and OS, respectively. Concordance index (C-index) and time-dependent AUC (from 3 – 132 months) were calculated to evaluate the model performance.
Results: 2,006 (58%) of patients (pts) were male; 1,141 (33%) received a non-myeloablative conditioning regimen; 326 (9.4%) were treated for a non-malignant condition; 1,207 (34.7%) were younger than 40 yo, 1,286 (37%) were 40-60 yo, and 984 (28.3%) were >60 yo. The C-index (95% CI) for NRM was: 0.592 (0.573, 0.612) for the HCT-CI; 0.626 (0.606, 0.645) for the aHCT-CI; 0.615 (0.595, 0.635) for the SCI; and 0.605 (0.585, 0.624) for the oHCT-CI. The C-index (95% CI) for OS was: 0.584 (0.570, 0.599) for the HCT-CI; 0.612 (0.598, 0.627) for the aHCT-CI; 0.588 (0.573, 0.602) for the SCI; and 0.591 (0.577, 0.606) for the oHCT-CI. The averaged time-dependent area under the curve (AUC) of the four systems, calculated for NRM over 3-132 months, was: 0.623 for the HCT-CI; 0.658 for the aHCT-CI; 0.631 for the SCI; and 0.614 for the oHCT-CI. The averaged AUC for OS was: 0.614 for HCT-CI, 0.643 for aHCT-CI, 0.603 for SCI, and 0.598 for oHCT-CI.
For 952 pts with a calculated SCI score of ‘0’, 281 have aHCT-CI score ‘0’, 485 have aHCT-CT score ‘1-2’, and 186 have aHCT-CI score ‘3+’.
These 3 groups are significantly different in OS (log-rank test p-value < 0.0001). The 3-year survival probabilities are 79.7% (74.8%, 84.8%), 71.1% (66.9%, 75.6%), and 57.1% (50.0%, 65.1%), respectively. [unable to compute median survival time because it was not reached]. Compared to the ‘0’ group, the hazard of death in ‘1-2’ group is 1.41 (1.04, 1.91) times higher and ‘3+’ group is 2.49 (1.78, 3.48) times higher.
They are also significantly different in NRM (Gray’s test p-value < 0.001). The cumulative incidences of NRM at 3-year are 7.2% (4.6%, 11%), 12% (8.9%, 15%), and 20% (14%, 26%), respectively. Compared to the ‘0’ group, the hazard of NRM in ‘1-2’ group is 1.56 (1.00, 2.46) times higher and ‘3+’ group is 2.75 (1.68, 4.49) times higher.
NRM and OS were significantly affected by the impact of the other comorbidities included in the HCT-CI and aHCI-CI.
Conclusions: Taken altogether, with all the limits due to a retrospective analysis, our findings show the more comprehensive aHCT-CI to perform the best. Pts labeled as having no comorbidity burden per the SCI (score 0) were further stratified into 3 groups with increasing hazards of NRM and overall mortality per the aHCT-CI, highlighting concerns over simplifying comorbidity evaluation. Moving forward, the aHCT-CI might be the more preferred comorbidity index for pt counseling and trial analyses. The oHCT-CI is not superior to models also including descriptive variables. Still, there is a need for novel biomarkers and even more accurate CIs.
Disclosures: Iovino: Pharmanutra SPA: Research Funding. Gauthier: Sobi, Legend Biotech, Janssen, Kite Pharma, a Gilead company, and MorphoSys: Consultancy; Sobi, Juno Therapeutics, a BMS company, Celgene, and Angiocrine Bioscience: Research Funding. Sorror: JAZZ pharmaceuticals: Consultancy, Honoraria.